254 related articles for article (PubMed ID: 34539621)
1. Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zeng J; Zhong Q; Feng X; Li L; Feng S; Fan Y; Song T; Huang Z; Wang X; Lin T
Front Immunol; 2021; 12():663602. PubMed ID: 34539621
[TBL] [Abstract][Full Text] [Related]
2. Conversion From Calcineurin Inhibitors to Mammalian Target-of-Rapamycin Inhibitors in Heart Transplant Recipients: A Meta-Analysis of Randomized Controlled Trials.
Qiu Y; Wang X; Fan J; Rao Z; Lu Y; Lin T
Transplant Proc; 2015 Dec; 47(10):2952-6. PubMed ID: 26707320
[TBL] [Abstract][Full Text] [Related]
3. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
Karpe KM; Talaulikar GS; Walters GD
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006750. PubMed ID: 28730648
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients.
Lim WH; Eris J; Kanellis J; Pussell B; Wiid Z; Witcombe D; Russ GR
Am J Transplant; 2014 Sep; 14(9):2106-19. PubMed ID: 25088685
[TBL] [Abstract][Full Text] [Related]
6. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
Montero N; Quero M; Melilli E; Pérez-Sáez MJ; Redondo-Pachón D; Bestard O; Crespo M; Cruzado JM; Pascual J
Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
Kumar J; Bridson JM; Sharma A; Halawa A
Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
[TBL] [Abstract][Full Text] [Related]
8. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
[TBL] [Abstract][Full Text] [Related]
9. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
Mallat SG; Tanios BY; Itani HS; Lotfi T; McMullan C; Gabardi S; Akl EA; Azzi JR
Clin J Am Soc Nephrol; 2017 Aug; 12(8):1321-1336. PubMed ID: 28576905
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials.
Yan HL; Zong HT; Cui YS; Li N; Zhang Y
Transplant Proc; 2014 Jun; 46(5):1302-13. PubMed ID: 24935293
[TBL] [Abstract][Full Text] [Related]
11. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH
Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744
[TBL] [Abstract][Full Text] [Related]
12. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.
Su L; Tam N; Deng R; Chen P; Li H; Wu L
Int Urol Nephrol; 2014 Oct; 46(10):2035-44. PubMed ID: 25027805
[TBL] [Abstract][Full Text] [Related]
13. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
[TBL] [Abstract][Full Text] [Related]
14. mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.
Avila CL; Zimmerer JM; Elzein SM; Pham TA; Abdel-Rasoul M; Bumgardner GL
Transplantation; 2016 Sep; 100(9):1898-906. PubMed ID: 27362313
[TBL] [Abstract][Full Text] [Related]
15. Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients.
Hasbal NB; Turgut D; Gok Oguz E; Ulu S; Gungor O
Ann Transplant; 2021 Mar; 26():e929279. PubMed ID: 33707409
[TBL] [Abstract][Full Text] [Related]
16. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.
Webster AC; Lee VW; Chapman JR; Craig JC
Transplantation; 2006 May; 81(9):1234-48. PubMed ID: 16699448
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
18. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
[TBL] [Abstract][Full Text] [Related]
19. Timing of mTORI usage and outcomes in kidney transplant recipients.
Lim LM; Kung LF; Kuo MC; Huang AM; Kuo HT
Int J Med Sci; 2021; 18(5):1179-1184. PubMed ID: 33526978
[TBL] [Abstract][Full Text] [Related]
20. Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers.
Cheung CY; Man Ma MK; Chak WL; Chau KF; Tang SCW
Oncotarget; 2017 Jul; 8(27):44833-44841. PubMed ID: 28160552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]